Do analysts rate CELZ or SNTI?

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 981.67%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is CELZ or SNTI more profitable?

Creative Medical Technology's return on equity of -88.38% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% Senti Biosciences N/A -532.05% -103.35%

Do analysts rate CELZ or EVAX?

Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 224.48%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is CELZ or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% Evaxion A/S N/A -73.56% -37.45%

Does the media refer more to CELZ or EVAX?

In the previous week, Creative Medical Technology had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Evaxion A/S. Creative Medical Technology's average media sentiment score of 0.85 beat Evaxion A/S's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Creative Medical Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CELZ or DARE?

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 383.09%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Dare Bioscience is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is CELZ or DARE more profitable?

Dare Bioscience's return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% Dare Bioscience N/A N/A -46.22%

Does the media favor CELZ or DARE?

In the previous week, Creative Medical Technology had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Dare Bioscience. Creative Medical Technology's average media sentiment score of 0.85 beat Dare Bioscience's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Creative Medical Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CELZ or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is CELZ or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -88.38% -84.71% NanoViricides N/A -87.90% -78.69%

Does the media refer more to CELZ or NNVC?

In the previous week, Creative Medical Technology had 1 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for NanoViricides. Creative Medical Technology's average media sentiment score of 0.85 beat NanoViricides' score of 0.28 indicating that Creative Medical Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Creative Medical Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SKYE or CELZ?

Skye Bioscience currently has a consensus target price of $9.80, suggesting a potential upside of 1,300.00%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Skye Bioscience is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SKYE or CELZ more profitable?

Creative Medical Technology's return on equity of -88.38% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% Creative Medical Technology N/A -88.38% -84.71%

Does the media prefer SKYE or CELZ?

In the previous week, Creative Medical Technology had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Skye Bioscience. Creative Medical Technology's average media sentiment score of 0.85 beat Skye Bioscience's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Creative Medical Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Creative Medical Technology (CELZ) Competitors

$1.97 +0.04 (+2.07%)

As of 04:00 PM Eastern

Compare

CELZ vs. SNTI, EVAX, DARE, NNVC, and SKYE

Should you buy Creative Medical Technology stock or one of its competitors? MarketBeat compares Creative Medical Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Creative Medical Technology include Senti Biosciences (SNTI), Evaxion A/S (EVAX), Dare Bioscience (DARE), NanoViricides (NNVC), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does Creative Medical Technology compare to Senti Biosciences?

Creative Medical Technology (NASDAQ:CELZ) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Creative Medical Technology had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Creative Medical Technology and 0 mentions for Senti Biosciences. Creative Medical Technology's average media sentiment score of 0.85 beat Senti Biosciences' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Positive
Senti Biosciences	Neutral

Creative Medical Technology's return on equity of -88.38% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Senti Biosciences	N/A	-532.05%	-103.35%

Creative Medical Technology has higher earnings, but lower revenue than Senti Biosciences. Creative Medical Technology is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	728.90	-$5.99M	-$2.14	N/A
Senti Biosciences	$20K	1,439.91	-$61.44M	-$1.92	N/A

Creative Medical Technology has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 981.67%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 1.7% of Creative Medical Technology shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Senti Biosciences beats Creative Medical Technology on 11 of the 16 factors compared between the two stocks.

How does Creative Medical Technology compare to Evaxion A/S?

Creative Medical Technology (NASDAQ:CELZ) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Evaxion A/S's return on equity of -73.56% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Evaxion A/S	N/A	-73.56%	-37.45%

Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 224.48%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Creative Medical Technology has higher earnings, but lower revenue than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	728.90	-$5.99M	-$2.14	N/A
Evaxion A/S	$7.53M	3.75	-$7.71M	-$1.47	N/A

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 1.7% of Creative Medical Technology shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Creative Medical Technology has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

In the previous week, Creative Medical Technology had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Evaxion A/S. Creative Medical Technology's average media sentiment score of 0.85 beat Evaxion A/S's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Creative Medical Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Evaxion A/S beats Creative Medical Technology on 9 of the 15 factors compared between the two stocks.

How does Creative Medical Technology compare to Dare Bioscience?

Creative Medical Technology (NASDAQ:CELZ) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Dare Bioscience's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Dare Bioscience	N/A	N/A	-46.22%

Creative Medical Technology has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	728.90	-$5.99M	-$2.14	N/A
Dare Bioscience	$1.03M	30.11	-$13.40M	-$0.95	N/A

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Creative Medical Technology has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 383.09%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Dare Bioscience is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Creative Medical Technology had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Dare Bioscience. Creative Medical Technology's average media sentiment score of 0.85 beat Dare Bioscience's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Creative Medical Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Dare Bioscience beats Creative Medical Technology on 9 of the 15 factors compared between the two stocks.

How does Creative Medical Technology compare to NanoViricides?

Creative Medical Technology (NASDAQ:CELZ) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NanoViricides' return on equity of -87.90% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
NanoViricides	N/A	-87.90%	-78.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Creative Medical Technology has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	728.90	-$5.99M	-$2.14	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Creative Medical Technology has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

In the previous week, Creative Medical Technology had 1 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for NanoViricides. Creative Medical Technology's average media sentiment score of 0.85 beat NanoViricides' score of 0.28 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Creative Medical Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NanoViricides beats Creative Medical Technology on 7 of the 13 factors compared between the two stocks.

How does Creative Medical Technology compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by company insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Creative Medical Technology has higher revenue and earnings than Skye Bioscience. Creative Medical Technology is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Creative Medical Technology	$10K	728.90	-$5.99M	-$2.14	N/A

In the previous week, Creative Medical Technology had 1 more articles in the media than Skye Bioscience. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Skye Bioscience. Creative Medical Technology's average media sentiment score of 0.85 beat Skye Bioscience's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Creative Medical Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Skye Bioscience has a beta of 2.95, indicating that its share price is 195% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market.

Skye Bioscience currently has a consensus target price of $9.80, suggesting a potential upside of 1,300.00%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Skye Bioscience is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Creative Medical Technology's return on equity of -88.38% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Creative Medical Technology	N/A	-88.38%	-84.71%

Summary

Skye Bioscience beats Creative Medical Technology on 9 of the 15 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELZ vs. The Competition

Export

Metric	Creative Medical Technology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.13M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-0.92	11.07	21.07	22.20
Price / Sales	728.90	334.82	530.36	110.15
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.97	8.29	10.79	6.50
Net Income	-$5.99M	$23.85M	$3.56B	$336.88M
7 Day Performance	-12.05%	5.21%	1.67%	-0.22%
1 Month Performance	-17.57%	2.19%	0.43%	0.77%
1 Year Performance	-19.26%	60.99%	32.84%	31.57%

Creative Medical Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELZ Creative Medical Technology	1.0398 of 5 stars	$1.97 +2.1%	N/A	-21.9%	$7.13M	$10K	N/A	5	News Coverage Gap Up
SNTI Senti Biosciences	3.1358 of 5 stars	$0.98 +2.5%	$10.00 +916.3%	-54.2%	$30.65M	$20K	N/A	4
EVAX Evaxion A/S	3.0317 of 5 stars	$3.65 -3.7%	$11.00 +201.4%	+47.4%	$30.44M	$7.53M	N/A	60	Gap Up
DARE Dare Bioscience	1.672 of 5 stars	$2.00 flat	$10.00 +400.0%	-27.3%	$29.98M	$1.16M	N/A	30
NNVC NanoViricides	0.5232 of 5 stars	$1.35 +0.4%	N/A	-7.7%	$29.55M	N/A	N/A	20	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELZ) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Creative Medical Technology (CELZ) Competitors

CELZ vs. SNTI, EVAX, DARE, NNVC, and SKYE

How does Creative Medical Technology compare to Senti Biosciences?

Summary

How does Creative Medical Technology compare to Evaxion A/S?

Summary

How does Creative Medical Technology compare to Dare Bioscience?

Summary

How does Creative Medical Technology compare to NanoViricides?

Summary

How does Creative Medical Technology compare to Skye Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Creative Medical Technology (CELZ) Competitors

CELZ vs. SNTI, EVAX, DARE, NNVC, and SKYE

How does Creative Medical Technology compare to Senti Biosciences?

Does the media refer more to CELZ or SNTI?

Is CELZ or SNTI more profitable?

Which has preferable valuation and earnings, CELZ or SNTI?

Which has more volatility & risk, CELZ or SNTI?

Do analysts rate CELZ or SNTI?

Do insiders & institutionals have more ownership in CELZ or SNTI?

Summary

How does Creative Medical Technology compare to Evaxion A/S?

Is CELZ or EVAX more profitable?

Do analysts rate CELZ or EVAX?

Which has stronger earnings & valuation, CELZ or EVAX?

Do insiders and institutionals have more ownership in CELZ or EVAX?

Which has more volatility and risk, CELZ or EVAX?

Does the media refer more to CELZ or EVAX?

Summary

How does Creative Medical Technology compare to Dare Bioscience?

Is CELZ or DARE more profitable?

Which has preferable valuation & earnings, CELZ or DARE?

Do insiders & institutionals believe in CELZ or DARE?

Which has more volatility & risk, CELZ or DARE?

Do analysts recommend CELZ or DARE?

Does the media favor CELZ or DARE?

Summary

How does Creative Medical Technology compare to NanoViricides?

Do institutionals and insiders have more ownership in CELZ or NNVC?

Is CELZ or NNVC more profitable?

Do analysts prefer CELZ or NNVC?

Which has better earnings & valuation, CELZ or NNVC?

Which has more risk & volatility, CELZ or NNVC?

Does the media refer more to CELZ or NNVC?

Summary

How does Creative Medical Technology compare to Skye Bioscience?

Do institutionals & insiders have more ownership in SKYE or CELZ?

Which has preferable earnings & valuation, SKYE or CELZ?

Does the media prefer SKYE or CELZ?

Which has more volatility and risk, SKYE or CELZ?

Do analysts recommend SKYE or CELZ?

Is SKYE or CELZ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools